Zydus Lifesciences, a leading Indian pharmaceutical company, has entered into a strategic partnership with Netherlands-based Synthon to commercialize a novel multiple sclerosis (MS) therapy in the United States. The collaboration aims to accelerate patient access to the treatment while leveraging the combined strengths of both firms in research, development, and regulatory expertise.